SWOG/ Support |
STUDY | R E G |
O P E N |
ARM | ACCR. GOAL |
TOTAL REGS. |
REGS. LAST 12 Month |
REGS. LAST 6 Month |
REGS. LAST 3 Month |
REGS. LAST 30 DAYS |
REGS. LAST 7 DAYS |
DATE OF FIRST REG. |
# of ACT. INSTs |
# of CURR IRBs |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
SWOG | S1803-MM, Maintenance, Len vs Len/Dara | 1 | Y | 0 Screening | 1100 | 878 | 338 | 158 | 80 | 23 | 4 | 08/13/2019 | 289 | 106 |
878 | 338 | 158 | 80 | 23 | 4 | |||||||||
2 | Y | 1 Lenalidomide | 405 | 167 | 79 | 39 | 12 | 2 | 08/13/2019 | |||||
2 Lenalidomide + Daratumumab | 396 | 165 | 78 | 37 | 15 | 4 | ||||||||
801 | 332 | 157 | 76 | 27 | 6 | |||||||||
3 | Y | 3 Continue Lenalidomide | 2 | 2 | 2 | 0 | 0 | 0 | 08/13/2019 | |||||
4 Stop Lenalidomide | 3 | 3 | 2 | 1 | 0 | 0 | ||||||||
5 Continue Lenalidomide + Dara | 6 | 6 | 4 | 1 | 0 | 0 | ||||||||
6 Stop Lenalidomide + Dara | 7 | 7 | 6 | 4 | 3 | 0 | ||||||||
18 | 18 | 14 | 6 | 3 | 0 | |||||||||
S2005-WM, Prev. Untreated, I/R +/- Venetoclax | 1 | Y | 2 I+R+Venetoclax | 62 | 1 | 1 | 1 | 0 | 0 | 0 | 01/05/2022 | 104 | 31 | |
1 | 1 | 1 | 0 | 0 | 0 | |||||||||
Yes | EAA181-Myel, Newly Dx, DRd=>DRd+/-Btz=>DR (EQUATE) | 0 | E | Total Registrations | 13 | 10 | 4 | 1 | 0 | 0 | 05/27/2021 | 179 | 64 | |
13 | 10 | 4 | 1 | 0 | 0 | |||||||||
1 | E | Total Registrations | 7 | 5 | 4 | 1 | 0 | 0 | 05/27/2021 | |||||
7 | 5 | 4 | 1 | 0 | 0 | |||||||||
2 | E | Total Registrations | 3 | 3 | 3 | 2 | 1 | 0 | 05/27/2021 | |||||
3 | 3 | 3 | 2 | 1 | 0 | |||||||||
No | A061402-Solitary Plasmacytoma, adj sys+Zol vs Zol | 0 | E | Total Registrations | 1 | 0 | 0 | 0 | 0 | 0 | 01/27/2017 | |||
1 | 0 | 0 | 0 | 0 | 0 | |||||||||
EAA173-MYEL, SMM, Rd +/- Daratumumab | 0 | E | Total Registrations | 37 | 10 | 5 | 1 | 0 | 0 | 01/08/2020 | 252 | 89 | ||
37 | 10 | 5 | 1 | 0 | 0 | |||||||||
1 | E | Total Registrations | 19 | 6 | 3 | 2 | 0 | 0 | 01/08/2020 | |||||
19 | 6 | 3 | 2 | 0 | 0 | |||||||||
Study | Registration/Phase | Open Date | # of ACT. INSTs |
# of CURR IRBs |
---|---|---|---|---|
S2005 WM, Prev. Untreated, I/R +/- Venetoclax | 2 Crossover | 24-Jun-21 | 104 | 31 |